Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Mifepristone Manufacturer Sues West Virginia Over Abortion Ban

GenBioPro Has Alleged That The Unborn Child Protection Act Is Unconstitutional

Executive Summary

Generic abortion pill manufacturer GenBioPro has mounted a case in West Virginia alleging that its state-level ban of abortion is unconstitutional, as it is pre-empted by the US Food and Drug Administration’s federal opinion that mifepristone is a safe and legal medication.

You may also be interested in...



Generic And Branded Mifepristone Remain On US Market Following Supreme Court Stay

GenBioPro will be able to continue selling its generic mifepristone, after the Supreme Court overruled a stay from the Fifth Circuit which could have seen generic approval rescinded and significant restrictions placed on the drug’s use. 

GenBioPro Suit Against FDA May Preserve Generic Mifepristone Approval

GenBioPro has filed a lawsuit against the FDA to try and preserve the approval of its generic mifepristone product, should the Supreme Court allow an order from a Texas judge to overrule the Food and Drug Administration’s approval of the drug.

Generics Bulletin Podcast – GenBioPro v. West Virginia: The Future Of Mifepristone In America, With Professor Greer Donley

Generics Bulletin spoke to University of Pittsburgh School of Law professor Greer Donley, a specialist in reproductive law, about generic mifepristone manufacturer GenBioPro’s lawsuit challenging West Virginia’s state-level restrictions on medical abortion access and its potential wider relevance for the industry.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel